Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Purpose: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab). Methods: This is a retrospective study involving 32 eyes from 29 patients; 18 were cases of neovascular AMD and 14 were cases of PCV. The best-corrected visual acuity (BCVA) and central macular thickness (CMT) of spectral-domain optical coherence tomography were evaluated. Results: BCVA and CMT improved from 0.58 to 0.55 (p = 0.005) and from 404 to 321 μm (p < 0.001), respectively, after switching to aflibercept. The 14 eyes that received 6 or more aflibercept injections remained stable at 0.81 to 0.81 and 321 to 327 μm (p = 1.0, 0.29), respectively, after 3 aflibercept injections. The 10 eyes that received 3 or more bevacizumab injections after 3 or more aflibercept injections worsened, from 0.44 to 0.47 and from 332 to 346 μm (p = 0.06, 0.05), respectively. The results showed similar improvement of BCVA and CMT in neovascular AMD and PCV. Conclusions: Aflibercept seems to be effective for improvement and maintenance of BCVA and CMT for neovascular AMD and PCV refractory to anti-VEGF. Switching from aflibercept back to bevacizumab treatment may not be a proper strategy.
Abstract
Purpose: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab). Methods: This is a retrospective study involving 32 eyes from 29 patients; 18 were cases of neovascular AMD and 14 were cases of PCV. The best-corrected visual acuity (BCVA) and central macular thickness (CMT) of spectral-domain optical coherence tomography were evaluated. Results: BCVA and CMT improved from 0.58 to 0.55 (p = 0.005) and from 404 to 321 μm (p < 0.001), respectively, after switching to aflibercept. The 14 eyes that received 6 or more aflibercept injections remained stable at 0.81 to 0.81 and 321 to 327 μm (p = 1.0, 0.29), respectively, after 3 aflibercept injections. The 10 eyes that received 3 or more bevacizumab injections after 3 or more aflibercept injections worsened, from 0.44 to 0.47 and from 332 to 346 μm (p = 0.06, 0.05), respectively. The results showed similar improvement of BCVA and CMT in neovascular AMD and PCV. Conclusions: Aflibercept seems to be effective for improvement and maintenance of BCVA and CMT for neovascular AMD and PCV refractory to anti-VEGF. Switching from aflibercept back to bevacizumab treatment may not be a proper strategy.
참고문헌 (21)
- Bressler NM, "Age-related macular degeneration is the leading cause of blindness", JAMA, 291, pp.1900~1901 (2004)
- Congdon N, "Causes and prevalence of visual impairment among adults in the United States", Arch Ophthalmol, 122, pp.477~485 (2004)
- Klaver CC, "Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study", Arch Ophthalmol, 116, pp.653~658 (1998)
- Chang AA, "Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration", Ophthalmology, 121, pp.188~192 (2014)
- Ho VY, "Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors", Am J Ophthalmol, 156, pp.23~28 (2013)
- Avery RL, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration", Ophthalmology, 113, pp.363~372 (2006)
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results", Ophthalmology, 119, pp.1388~1398 (2012)
- Folk JC, "Ranibizumab therapy for neovascular age-related macular degeneration", N Engl J Med, 363, pp.1648~1655 (2010)
- Otsuji T, "Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)", Clin Ophthalmol, 7, pp.1487~1490 (2013)
- Binder S, "Loss of reactivity in intravitreal anti-VEGF therapy:tachyphylaxis or tolerance?", Br J Ophthalmol, 96, pp.1~2 (2012)
- Schaal S, "Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?", Ophthalmology, 115, pp.2199~2205 (2008)
- Yannuzzi LA, "Idiopathic polypoidal choroidal vasculopathy (IPCV)", Retina, 10, pp.1~8 (1990)
- Gomi F, "One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients", Ophthalmology, 115, pp.141~146 (2008)
- Hikichi T, "One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients", Am J Ophthalmol, 154, pp.117~124 (2012)
- Akaza E, "Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy", Jpn J Ophthalmol, 55, pp.39~44 (2011)
- Wykoff CC, "SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results", Ophthalmic Surg Lasers Imaging Retina, 44, pp.121~126 (2013)
- Papadopoulos N, "Binding and neutralization of vascular endothelial growth factor (VEGF)and related ligands by VEGF Trap, ranibizumab and bevacizumab", Angiogenesis, 15, pp.171~185 (2012)
- Stewart MW, "Predicted biological activity of intravitreal VEGF Trap", Br J Ophthalmol, 92, pp.667~668 (2008)
- Heier JS, "Intravitreal afliber cept (VEGF trap-eye) in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)
- Cho H, "Aflibercept for exudative AMD with persistent fluid on ranibizumab and", or bevacizumab, 2013, pp.97, 1032~1035
- Yonekawa Y, "Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration", Am J Ophthalmol, 156, pp.29~35 (2013)